机构:The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
Lokesh Kukreja
Catherine J. Li
论文数: 0引用数: 0
h-index: 0
机构:The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
Catherine J. Li
Sathyapriya Ezhilan
论文数: 0引用数: 0
h-index: 0
机构:The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
Sathyapriya Ezhilan
Vishwanath R. Iyer
论文数: 0引用数: 0
h-index: 0
机构:The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
Vishwanath R. Iyer
John S. Kuo
论文数: 0引用数: 0
h-index: 0
机构:The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
John S. Kuo
机构:
[1] The University of Texas at Austin,Department of Neurosurgery, Dell Medical School
[2] The University of Texas,Department of Molecular Biosciences, LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School
[3] The University of Texas at Austin,Department of Neurosurgery, Mulva Clinic for the Neurosciences and LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School
[4] China Medical University,Graduate Institute of Biomedical Sciences
Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and complex, leading to poor prognoses and creating a need for new treatment modalities. Aberrant epigenetics define these types of tumors, with underlying changes in DNA methylation, histone modifications, chromatin structure and noncoding RNAs. Epigenetic-targeted therapies are an alternative that have the potential to reverse the epigenetic deregulation underpinning brain malignancies. Various drugs targeting epigenetic regulators have shown promise in preclinical and clinical testing. In this review, we highlight some of the recent emerging epigenetic targeted therapies for brain tumors being evaluated in the discovery phase and in clinical trials.
机构:
Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
Sermer, David
Pasqualucci, Laura
论文数: 0引用数: 0
h-index: 0
机构:
Columbia Univ, Inst Canc Genet, New York, NY USAMem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
Pasqualucci, Laura
Wendel, Hans-Guido
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
Wendel, Hans-Guido
Melnick, Ari
论文数: 0引用数: 0
h-index: 0
机构:
Weill Cornell Med Coll, New York, NY USAMem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
Melnick, Ari
Younes, Anas
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USAMem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA